Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Eric Kimble has been named chief commercial officer of Adagio Therapeutics. Kimble was recently chief commercial officer at Entasis Therapeutics. Adagio has also named Ed Campanaro as senior vice president of clinical operations. Campanaro most recently served as senior vice president of clinical operations at Artugen Therapeutics.
Hong Jiang, serial entrepreneur and a biotech investor, has been named chief operating officer of Aegis Life.
Agios Pharmaceuticals has named Jonathan Biller as chief financial officer and head of legal and corporate affairs. Recently, Biller was chief legal officer at Agios.
Ercem Atillasoy has been named chief regulatory and safety officer of AlloVir. He was former vice president and therapeutic area head of vaccines and infectious disease at Merck Research Laboratories.
Black Diamond Therapeutics
Rachel Humphrey has been named chief medical officer of Black Diamond Therapeutics. Prior to this appointment, Humphrey was chief medical officer of CytomX Therapeutics. Black Diamond also named Fang Ni, former principal and investment team member at Versant Ventures, as the company’s new chief business officer.
Andrew Hirsch has taken the helm of C4 Therapeutics as the company’s CEO. Hirsch was most recently chief financial officer and head of corporate development at Agios Pharmaceuticals.
CavoGene LifeSciences has appointed Daniel Jorgensen to CEO of the company. Jorgensen most recently served as vice president of AMAG Pharmaceuticals.
Diffusion Pharmaceuticals has appointed Robert Cobuzzi to president and CEO. Cobuzzi was previously president and CEO of MitoCUREia.
Patrik Jonsson has been named senior vice president and chief customer officer of Eli Lilly. Formerly, Jonsson was president and general manager of Eli Lilly Japan.
FibroGen has found its new chief scientific officer in Percy Carter, former global head of discovery sciences at Janssen.
Invivoscribe has appointed Loui Madakamutil to the role of chief scientific officer. Madakamutil most recently served as senior vice president and head of discovery and preclinical development at Nektar Therapeutics.
Anna Eramo has been named chief medical officer of LB Pharmaceuticals. Eramo most recently served as clinical and medical affairs head of the U.S. division of Lundbeck.
Ali Fattaey has been named CEO of MetaboMed. Previously, Fattaey was president and CEO of Boston-based biotech company Curis.
Sergie Letser has been appointed to the business development team at Nanoform. Prior to this appointment, Letser led U.S. business development activities at Porton Pharma Solutions.
National Pharmaceutical Council
The National Pharmaceutical Council has named Robert Dubois as interim president and CEO. Most recently, Dubois served as the organization’s chief science officer and executive vice president.
Fredrik Järrsten has been appointed by Oasmia Pharmaceutical to the role of chief financial officer. Järrsten is currently the chief financial officer and deputy CEO of investor company Karolinska Development.
Oncopeptides has appointed Mohamed Ladha to the role of general manager of the company’s U.S. business unit. Prior to joining Oncopeptides, Ladha was vice president and head of commercial, operations and medical affairs at Tocagen.
Phosplatin Therapeutics has added Joseph O’Donnell to its staff as the company’s interim chief medical officer. O’Donnell was previously Elizabeth Decamp McInerney professor of medicine at the Geisel School of Medicine at Dartmouth University. Jason Summa, former oncology director and clinical project scientist with Janssen, has also been named by Phosplatin as vice president of clinical development.
PrecisionLife has named Simon Beaulah as senior vice president of healthcare and head of U.S. operations. Beaulah was most recently director of healthcare at Linguamatics.
Cassandra Matney has been named senior medical director of Premier Research. Formerly, Matney was senior manager of medical affairs liaison at Astellas Pharma.
ReCode Therapeutics has appointed Mukul Agarwal to the role of chief business officer. Agarwal was most recently vice president of corporate development at Forty Seven. Vladimir Kharitonov, former vice president of research and development at Pacira Pharmaceuticals, has been appointed by ReCode to the role of senior vice president of chemistry, manufacturing and controls.
Ed Rebar has been named chief technology officer of Sana Biotechnology. Previously, Rebar was chief technology officer at Sangamo Therapeutics. Sana Biotechnology has also named Terry Fry, former professor of pediatrics, hematology and immunology as well as director of cancer immunotherapy at the University of Colorado School of Medicine and Children’s Hospital Colorado, as senior vice president and head of T-cell therapeutics.
Rosh Dias has been named chief medical officer of Spruce Biosciences. Previously, Dias was the chief medical officer of Indivior.
Vijay Reddy has been named chief research and development officer of Tmunity Therapeutics. Previously, Reddy was a medical oncologist at MD Anderson Cancer Center. Simona King has also joined Tmunity in the role of chief financial officer. King was recently the vice president of finance at Emergent BioSolutions.
Global biotherapeutics company Transcenta Holding has appointed Charlie Qi as its senior vice president of global clinical development. Qi was recently head of oncology product development at Roche Global Product Development Center.
Jason Smith has been appointed general counsel and chief compliance officer of UroGen Pharma. Most recently, Smith was chief counsel of oncology at Pfizer. UroGen has also named Polly Murphy as chief business officer. Murphy was recently Pfizer’s vice president for early commercial development in the oncology business unit.